Camurus is a Swedish specialty pharmaceutical company developing and commercializing innovative medicines based on its proprietary FluidCrystal technology platform for long-acting injectable drug delivery. The company focuses on rare diseases, oncology, and CNS disorders.
Company Info
Upcoming Milestones & Key Dates
FDA decision on Oclaiz acromegaly resubmission (PDUFA)
Phase 3 readout of treprostinil in PAH
Clinical Development Pipeline
Recent News
Camurus received a second Complete Response Letter from FDA for its acromegaly candidate, while Teva provided fresh details on its multi-year workforce reduction plan covering both its generics and specialty operations.
Sweden's Camurus received a second Complete Response Letter from the FDA for its acromegaly treatment, while Teva Pharmaceutical detailed workforce reductions tied to the ongoing divestiture of its API manufacturing business.
Leadership Team
Careers & Job Openings